Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INBRX-106 · 1 trial · 1 indication
ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first).
OS is the time from randomization to death due to any cause
| Arm | Type | Description |
|---|---|---|
| INBRX-106 plus pembrolizumab | EXPERIMENTAL | Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3) |
| pembrolizumab monotherapy (+ placebo in phase 3 part) | ACTIVE_COMPARATOR | Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3) |
| Name | Type | Description |
|---|---|---|
| INBRX-106 | DRUG | INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3) |
| Pembrolizumab | DRUG | Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3) |
Inclusion Criteria: * Has histologically or cytologically confirmed diagnosis of metastatic, recurrent head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies. * Has tumor PD-L1 expression of CPS ≥20. Tumor tissue must be provided for PD-L1 biomarker analysis. ...
INBRX-106 is an investigational small molecule being developed for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Phase 2 clinical development, evaluated in combination with pembrolizumab as a first-line therapy for patients with PD-L1 CPS≥20 HNSCC.
INBRX-106 is being developed by Inhibrx Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker INBX. The company is conducting a Phase 2 clinical trial of INBRX-106 in combination with pembrolizumab for the treatment of Head and Neck Squamous Cell Carcinoma.
INBRX-106 is in Phase 2 clinical development. It is being studied in an active, not recruiting clinical trial for Head and Neck Squamous Cell Carcinoma. The drug is investigational and has not been approved by regulatory authorities.
INBRX-106 is being evaluated in one active Phase 2 clinical trial, NCT06295731. This randomized, double-blind, active-controlled study enrolls 410 participants with Head and Neck Squamous Cell Carcinoma and is testing INBRX-106 in combination with pembrolizumab as first-line therapy in patients with PD-L1 CPS≥20.
Yes, INBRX-106 is a small molecule therapeutic. It is being developed for the oncology indication of Head and Neck Squamous Cell Carcinoma and is currently in Phase 2 clinical trials.